News
The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.
Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...
Arcturus has made progress in cost-cutting and focusing on CF and OTC deficiency. Click here to find out the factors that ...
Professor Hirohide Saito (Department of Life Science Frontiers at CiRA / The University of Tokyo) and Assistant Professor ...
The inaccurate rumours refer to a study looking at excess deaths during the pandemic in the German city of Frankfurt am Main.
If we don’t invest in technologies like mRNA vaccines for pandemic influenza now, once a virus starts going human-to-human, ...
In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...
Chronic heart failure and hypoalbuminaemia are linked to a poor antibody response at 3 months after the third dose of the ...
11h
Zacks Investment Research on MSNMRNA Stock Jumps on CDC's Revised RSV Vaccine RecommendationsShares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...
Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...
The world's first mRNA vaccine against Elephant Endotheliotropic Herpesvirus (EEHV) has reportedly shown promising results, ...
The revamped and “more anti-vax skewed ACIP committee” at the CDC “has a bone to pick with mRNA vaccines,” according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results